[{"id":"ab6aba80-1e3b-47d5-8868-86f0127b9e88","acronym":"","url":"https://clinicaltrials.gov/study/NCT05616624","created_at":"2023-02-13T16:00:27.839Z","updated_at":"2024-07-02T16:35:00.642Z","phase":"Phase 1/2","brief_title":"ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers","source_id_and_acronym":"NCT05616624","lead_sponsor":"Washington University School of Medicine","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • docetaxel • Hepacid (pegargiminase)"],"overall_status":"Recruiting","enrollment":" Enrollment 114","initiation":"Initiation: 04/05/2023","start_date":" 04/05/2023","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2032","study_completion_date":" 12/31/2032","last_update_posted":"2024-05-27"},{"id":"366da270-8f09-44d6-be12-90adac16a8b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06085729","created_at":"2023-10-17T15:12:33.301Z","updated_at":"2024-07-02T16:35:16.807Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)","source_id_and_acronym":"NCT06085729","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • PTEN • RB1","pipe":" | ","alterations":" TP53 mutation • PTEN mutation • LDH elevation","tags":["TP53 • PTEN • RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • PTEN mutation • LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Rybrevant (amivantamab-vmjw) • Tepmetko (tepotinib) • cabazitaxel • Hepacid (pegargiminase)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/29/2024","start_date":" 02/29/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-03-01"},{"id":"6ed5215e-5228-4ee7-8f80-16805303ee59","acronym":"","url":"https://clinicaltrials.gov/study/NCT03922880","created_at":"2021-01-18T19:17:57.870Z","updated_at":"2024-07-02T16:35:56.988Z","phase":"Phase 1","brief_title":"Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma","source_id_and_acronym":"NCT03922880","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" GNAQ • GNA11 • CYSLTR2 • PLCB4","pipe":"","alterations":" ","tags":["GNAQ • GNA11 • CYSLTR2 • PLCB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Hepacid (pegargiminase)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 04/16/2019","start_date":" 04/16/2019","primary_txt":" Primary completion: 01/20/2023","primary_completion_date":" 01/20/2023","study_txt":" Completion: 01/20/2023","study_completion_date":" 01/20/2023","last_update_posted":"2023-01-26"},{"id":"add3bb81-2182-493a-bebb-02f5febddd99","acronym":"","url":"https://clinicaltrials.gov/study/NCT03498222","created_at":"2021-01-18T17:13:22.138Z","updated_at":"2024-07-02T16:36:49.560Z","phase":"Phase 1","brief_title":"Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin","source_id_and_acronym":"NCT03498222","lead_sponsor":"Queen Mary University of London","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • ALK positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • carboplatin • pemetrexed • Hepacid (pegargiminase)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/01/2018","start_date":" 06/01/2018","primary_txt":" Primary completion: 01/31/2020","primary_completion_date":" 01/31/2020","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2020-02-25"},{"id":"f6d3128b-a533-46ab-8f10-064cb26f1252","acronym":"","url":"https://clinicaltrials.gov/study/NCT01948843","created_at":"2021-01-18T08:50:04.368Z","updated_at":"2024-07-02T16:37:32.768Z","phase":"Phase 1","brief_title":"Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer","source_id_and_acronym":"NCT01948843","lead_sponsor":"Polaris Group","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • Hepacid (pegargiminase)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 04/01/2014","start_date":" 04/01/2014","primary_txt":" Primary completion: 04/01/2016","primary_completion_date":" 04/01/2016","study_txt":" Completion: 04/01/2016","study_completion_date":" 04/01/2016","last_update_posted":"2016-04-14"}]